FullCare

This combination tablet is indicated for use in improving the nutritional status of women throughout the pregnancy. This is a micronutrient supplements but not a substitute of balanced diet during pregnancy.

Each film-coated tablet contains:

• Vitamin A (Retinyl Acetate): 800 mcg RAE
• Vitamin C (Ascorbic Acid): 70 mg
• Vitamin D (Cholecalciferol): 5 mcg (200 IU)
• Vitamin E (Vitamin E Acetate): 10 mg α-TE
• Vitamin B1 (Thiamine Mononitrate): 1.4 mg
• Vitamin B2 (Riboflavin): 1.4 mg
• Vitamin B3 (Niacinamide): 18 mg NE
• Vitamin B6 (Pyridoxine HCl): 1.9 mg
• Folic Acid: 680 mcg DFE (400 mcg)
• Vitamin B12 (Cyanocobalamin): 2.6 mcg
• Iron (Ferrous Fumarate): 30 mg
• Iodine (Potassium Iodide): 150 mcg
• Zinc (Zinc Gluconate): 15 mg
• Selenium (Sodium Selenite): 65 mcg
• Copper (Cupric Gluconate): 2 mg

Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy. This combination is a UNIMMAP MMS product, required during pregnancy due to the increased nutritional needs of the mother and the growing foetus, even if the mother has access to a sufficient diet. It aids healthy functioning of her body and helps to avoid her baby from being born too soon and too small, as well as other long-term implications on the health of the child. Moreover, This combination prevents anemia, a condition when the body does not produce enough red blood cells. Micronutrient deficiency is one of the major risk factors of LBW.

Evidence shows that the provision of MMS for women starting early in pregnancy provides clear benefits for both women and their unborn and newborn infants, beyond IFA supplementation alone. The MMS can improve birth outcomes significantly by reducing the risk of LBW (12%), being born small-for-gestational age (SGA) at 8%, and preterm births. The 2017 Lancet meta-analysis established that MMS significantly reduces the risk of following health outcomes:

• Reduces the risk of babies being born with a low birth weight
• Reduces the risk of small-for-gestational age births
• Reduces preterm birth
• Reduces the risk of neonatal mortality Objective
• To establish Multiple Micronutrient Supplements (MMS) as a highly impactful solution for reducing Low Birth Weight (LBW)
• To replace Iron Folic Acid (IFA) by MMS in Bangladesh hence reduce the prevalence of Low Birth Weight (LBW).

This combination is the first ever UNIMMAP formulated and WHO recommended Multiple Micronutrient Supplements (MMS) in Bangladesh from LMICs for fulfilling the additional nutritional requirements during pregnancy to reduce the prevalence of LBW.

Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WFIO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy. Micronutrients are only needed in very small quantities but are essential for normal physiological function, growth and development. Deficiencies of micronutrients such as vitamin A, iron, iodine and folate are particularly very common during pregnancy due to increased nutrient requirements of the mother and developing fetus. These deficiencies can negatively impact the health of the mother, her pregnancy, as well as the health of the newborn baby. Recent evidence shows that the provision of MMS for women starting early in pregnancy provides clear benefits for both women and their unborn and newborn infants, beyond IFA supplementation alone. MMS can improve birth outcomes significantly by reducing the risk of low birth weight (LBW), being born small-for-gestational age (SGA), and preterm births.

Take only one tablet daily starting as soon as possible after conception and continue to use 180 tablets for 6 months throughout the pregnancy or as directed by the physician. It is not recommended for children and adolescents.

No drug interactions have been reported.

Individuals with known hypersensitivity to any of the ingredients.

Daily intake of recommended dose has no risk of adverse health effects in almost all individuals.

This is recommended to use only during pregnancy.

Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years. In case of accidental overdose, call a doctor or immediately visit the nearest hospital.

Tolerable Upper Limit (UL) of ingredients are significantly above the levels of the UNIMMAP formulation, the highest level of nutrient intake that is likely to pose no risk of adverse health effects for almost all individuals in the general population. However, overdose with iron produces increased risk of gastrointestinal side effects that includes constipation, nausea, vomiting, diarrhea, stomach pain, loss of appetite and requires doctor’s consultation.

Keep out of the reach of children. Keep between 15°C to 30°C, protect from light and humidity.